These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

558 related articles for article (PubMed ID: 20170765)

  • 1. Immunogenic properties of a recombinant fusion protein containing the C-terminal 19 kDa of Plasmodium falciparum merozoite surface protein-1 and the innate immunity agonist FliC flagellin of Salmonella typhimurium.
    Bargieri DY; Leite JA; Lopes SC; Sbrogio-Almeida ME; Braga CJ; Ferreira LC; Soares IS; Costa FT; Rodrigues MM
    Vaccine; 2010 Apr; 28(16):2818-26. PubMed ID: 20170765
    [TBL] [Abstract][Full Text] [Related]  

  • 2. New malaria vaccine candidates based on the Plasmodium vivax Merozoite Surface Protein-1 and the TLR-5 agonist Salmonella Typhimurium FliC flagellin.
    Bargieri DY; Rosa DS; Braga CJ; Carvalho BO; Costa FT; Espíndola NM; Vaz AJ; Soares IS; Ferreira LC; Rodrigues MM
    Vaccine; 2008 Nov; 26(48):6132-42. PubMed ID: 18804504
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Long-lasting protective immune response to the 19-kilodalton carboxy-terminal fragment of Plasmodium yoelii merozoite surface protein 1 in mice.
    Jeamwattanalert P; Mahakunkijcharoen Y; Kittigul L; Mahannop P; Pichyangkul S; Hirunpetcharat C
    Clin Vaccine Immunol; 2007 Apr; 14(4):342-7. PubMed ID: 17314232
    [TBL] [Abstract][Full Text] [Related]  

  • 4. TLR5-dependent immunogenicity of a recombinant fusion protein containing an immunodominant epitope of malarial circumsporozoite protein and the FliC flagellin of Salmonella Typhimurium.
    Camacho AG; Teixeira LH; Bargieri DY; Boscardin SB; Soares IS; Nussenzweig RS; Nussenzweig V; Rodrigues MM
    Mem Inst Oswaldo Cruz; 2011 Aug; 106 Suppl 1():167-71. PubMed ID: 21881771
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Stability and potency of the Plasmodium falciparum MSP1-19/AMA-1(III) chimeric vaccine candidate with Montanide ISA720 adjuvant.
    Xue X; Ding F; Zhang Q; Pan X; Qu L; Pan W
    Vaccine; 2010 Apr; 28(18):3152-8. PubMed ID: 20197139
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immunogenicity and protective efficacy of Escherichia coli expressed Plasmodium falciparum merozoite surface protein-1(42) using human compatible adjuvants.
    Sachdeva S; Mohmmed A; Dasaradhi PV; Crabb BS; Katyal A; Malhotra P; Chauhan VS
    Vaccine; 2006 Mar; 24(12):2007-16. PubMed ID: 16377036
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immunogenicity of recombinant proteins consisting of Plasmodium vivax circumsporozoite protein allelic variant-derived epitopes fused with Salmonella enterica Serovar Typhimurium flagellin.
    Leal MT; Camacho AG; Teixeira LH; Bargieri DY; Soares IS; Tararam CA; Rodrigues MM
    Clin Vaccine Immunol; 2013 Sep; 20(9):1418-25. PubMed ID: 23863502
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antigenicity and immunogenicity of the N-terminal 33-kDa processing fragment of the Plasmodium falciparum merozoite surface protein 1, MSP1: implications for vaccine development.
    Yuen D; Leung WH; Cheung R; Hashimoto C; Ng SF; Ho W; Hui G
    Vaccine; 2007 Jan; 25(3):490-9. PubMed ID: 16949181
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Influence of deleting 9 amino acid residues at N-terminus on immunogenicity of a Plasmodium falciparum chimeric protein].
    Zhang QF; Pan WQ; Qu L; Xue XY
    Sheng Wu Hua Xue Yu Sheng Wu Wu Li Xue Bao (Shanghai); 2003 Apr; 35(4):345-9. PubMed ID: 12673388
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy of two alternate vaccines based on Plasmodium falciparum merozoite surface protein 1 in an Aotus challenge trial.
    Stowers AW; Cioce V; Shimp RL; Lawson M; Hui G; Muratova O; Kaslow DC; Robinson R; Long CA; Miller LH
    Infect Immun; 2001 Mar; 69(3):1536-46. PubMed ID: 11179324
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immunogenicity of a recombinant malaria vaccine candidate, domain I+II of AMA-1 ectodomain, from Indian P. falciparum alleles.
    Lalitha PV; Biswas S; Pillai CR; Saxena RK
    Vaccine; 2008 Aug; 26(35):4526-35. PubMed ID: 18590786
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Plasmodium falciparum anti-MSP1-19 antibodies induced by MSP1-42 and MSP1-19 based vaccines differed in specificity and parasite growth inhibition in terms of recognition of conserved versus variant epitopes.
    Hui G; Hashimoto C
    Vaccine; 2007 Jan; 25(5):948-56. PubMed ID: 17023096
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immunogenicity of a chimeric Plasmodium falciparum merozoite surface protein vaccine in Aotus monkeys.
    Burns JM; Miura K; Sullivan J; Long CA; Barnwell JW
    Malar J; 2016 Mar; 15():159. PubMed ID: 26975721
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evaluation of immune responses to a Plasmodium vivax CSP-based recombinant protein vaccine candidate in combination with second-generation adjuvants in mice.
    Lumsden JM; Nurmukhambetova S; Klein JH; Sattabongkot J; Bennett JW; Bertholet S; Fox CB; Reed SG; Ockenhouse CF; Howard RF; Polhemus ME; Yadava A
    Vaccine; 2012 May; 30(22):3311-9. PubMed ID: 22425788
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The pan HLA DR-binding epitope improves adjuvant-assisted immunization with a recombinant protein containing a malaria vaccine candidate.
    Rosa DS; Tzelepis F; Cunha MG; Soares IS; Rodrigues MM
    Immunol Lett; 2004 Apr; 92(3):259-68. PubMed ID: 15081621
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immunogenicity and in vitro protective efficacy of a polyepitope Plasmodium falciparum candidate vaccine constructed by epitope shuffling.
    Cai Q; Peng G; Bu L; Lin Y; Zhang L; Lustigmen S; Wang H
    Vaccine; 2007 Jul; 25(28):5155-65. PubMed ID: 17548134
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Differential effects of C3d on the immunogenicity of gene gun vaccines encoding Plasmodium falciparum and Plasmodium berghei MSP1(42).
    Weiss R; Gabler M; Jacobs T; Gilberger TW; Thalhamer J; Scheiblhofer S
    Vaccine; 2010 Jun; 28(28):4515-22. PubMed ID: 20438877
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Adenovectors induce functional antibodies capable of potent inhibition of blood stage malaria parasite growth.
    Bruder JT; Stefaniak ME; Patterson NB; Chen P; Konovalova S; Limbach K; Campo JJ; Ettyreddy D; Li S; Dubovsky F; Richie TL; King CR; Long CA; Doolan DL
    Vaccine; 2010 Apr; 28(18):3201-10. PubMed ID: 20188680
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evaluation of the safety and immunogenicity of Plasmodium falciparum apical membrane antigen 1, merozoite surface protein 1 or RTS,S vaccines with adjuvant system AS02A administered alone or concurrently in rhesus monkeys.
    Pichyangkul S; Tongtawe P; Kum-Arb U; Yongvanitchit K; Gettayacamin M; Hollingdale MR; Limsalakpetch A; Stewart VA; Lanar DE; Dutta S; Angov E; Ware LA; Bergmann-Leitner ES; House B; Voss G; Dubois MC; Cohen JD; Fukuda MM; Heppner DG; Miller RS
    Vaccine; 2009 Dec; 28(2):452-62. PubMed ID: 19857448
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Humoral immune response in mice to hybrid nucleic acid vaccines containing Plasmodium falciparum merozoite surface protein 1 block 17-based gene].
    Miao J; Li X; Xue C; Zhen R; Liu Z; Qin E; Yu Q
    Zhongguo Ji Sheng Chong Xue Yu Ji Sheng Chong Bing Za Zhi; 1999; 17(5):302-4. PubMed ID: 12563865
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 28.